admin | April 30, 2021
June 12, 2014
Geron Corp. announced today that the FDA has removed the partial clinical hold on its clinical trial of imetelstat in myelofibrosis. The hold for polycythemia vera and essential thrombocythemia remails. Cick here for the full story.
Previous reports on Imetelstat:
Geron’s Imetelstat put on partial clinical hold for MF trials
Telomerase Inhibitor Imetelstat Shows Promise in Myelofibrosis